Alley Michael R K, Baker Stephen J, Beutner Karl R, Plattner Jacob
Anacor Pharmaceuticals, 1060 East Meadow Circle, Palo Alto, CA 94303, USA.
Expert Opin Investig Drugs. 2007 Feb;16(2):157-67. doi: 10.1517/13543784.16.2.157.
Onychomycosis is a fungal infection of the fingernails and toenails that results in thickening, discoloration, splitting of the nails and lifting of the nail from the nail bed. The disease is caused by dermatophytes and has a high incidence within the general population, especially among older individuals. Present treatment options include both oral and topical drugs, with oral therapies giving better outcomes; however, neither of these treatment options provides high cure rates that are durable. The difficulty in treating onychomycosis results from the deep-seated nature of the infection within the nail unit (nail plate, nail bed and surrounding tissue) and the inability of drugs to effectively reach all sites. Ongoing drug development activities have focused on novel delivery technologies to facilitate penetration of existing antifungal drugs through the nail plate and on the discovery of inherently penetrable antifungals. AN-2690 represents an oxaborole antifungal that is designed to penetrate the nail plate and is showing promising results in clinical trials.
甲癣是一种手指甲和脚趾甲的真菌感染,会导致指甲增厚、变色、裂开以及指甲与甲床分离。该疾病由皮肤癣菌引起,在普通人群中发病率较高,尤其是在老年人中。目前的治疗选择包括口服和外用药物,口服疗法效果更佳;然而,这些治疗选择都无法提供持久的高治愈率。治疗甲癣的困难源于感染在甲单位(甲板、甲床和周围组织)内的深层性质以及药物无法有效到达所有部位。正在进行的药物研发活动集中在新型给药技术上,以促进现有抗真菌药物穿透甲板,以及发现具有内在穿透性的抗真菌药物。AN - 2690是一种硼酸硼烷类抗真菌药物,旨在穿透甲板,并且在临床试验中显示出有前景的结果。